CGM for Type 2 Diabetes: What Controlled Trials Show

Continuous glucose monitors can help people with type 2 diabetes improve blood sugar control, but the best controlled evidence supports a package: CGM plus education, goal-setting, feedback, and follow-up. It does not show that buying a sensor and watching the graph does the job by itself.

That distinction matters because CGM is now marketed far beyond insulin dosing. The appeal is obvious: immediate feedback seems more persuasive than a laboratory value every few months. Yet controlled trials in pharmacologically managed type 2 diabetes show a modest glycemic benefit at about three months, while pooled evidence does not show a statistically significant improvement in treatment adherence. The hardware may be useful, but it has not earned sole credit for the outcomes.

The effect in treated type 2 diabetes is real, but modest

The broadest quantitative review in this evidence base, Kamei et al.'s 2022 systematic review and meta-analysis, examined wearable interventions for chronic disease management. In its diabetes subgroup, the intervention groups had an average HbA1c reduction of 0.69 percentage points versus comparators (mean difference −0.69%; 95% CI, −1.28 to −0.10; p=.02). They also had lower fasting blood glucose by 32.39 mg/dL (95% CI, −48.07 to −16.72; p<.0001).

At three months, participants were more likely to achieve more than 2% weight loss: relative risk 2.20 (95% CI, 1.38 to 3.50; p=.0009). That relative effect sounds large, but the review does not provide the underlying absolute rates here, so it cannot tell a reader how many additional people reached that threshold. Nor does a three-month weight endpoint establish durable weight loss.

An HbA1c reduction around half to seven-tenths of a percentage point can matter clinically, especially across a population with type 2 diabetes. But HbA1c and fasting glucose are surrogate measures, not direct evidence that CGM reduced complications, hospitalizations, or mortality. The studies summarized here also do not supply six- or 12-month outcomes, so they cannot answer whether early gains persist after the novelty of glucose graphs wears off.

The trials tested support programs, not isolated sensors

The central limitation is unusually consequential: every randomized trial included in Kamei's review paired the wearable with education or behavioral support. The packages included elements such as goal-setting, real-time feedback, text messages, and virtual social support. There was no device-only study arm anywhere in that meta-analysis.

That design can show whether the package outperforms its comparator. It cannot separate the effect of the sensor from the effect of coaching, reminders, accountability, or the clinical attention that comes with using it. A CGM may make feedback more timely and more specific; it may also simply be the reason a person enters a more intensive self-management program. The trials do not resolve which component produced how much of the HbA1c change.

A 2026 randomized trial by Lahiri et al. is relevant because it examined sequential CGM use with and without an exercise tracker in people with type 2 diabetes. It reported improved glycemic control with CGM deployment, but it likewise evaluated CGM and education as a combined behavioral intervention. Adding an activity tracker is a sensible question for a multi-device routine; it still does not create a clean test of CGM hardware without behavioral support.

The same pattern appears in clinical implementation. Aleppo et al.'s 2023 prospective, single-arm telehealth study evaluated a virtual diabetes-care model that integrated CGM with training, education from a diabetes care and education specialist, and behavioral-health support. It illustrates how CGM is often used in practice: as one part of care delivery, rather than a solitary intervention. Because the study was single-arm, it cannot establish that CGM or any other individual program component caused the outcomes.

The adherence result complicates the marketing story

Wearable marketing often assumes a simple chain: visible data changes behavior, and changed behavior improves health. Kamei et al. found no statistically significant pooled improvement in treatment adherence across wearable interventions, disease groups, and co-intervention designs (p=.38). A p value above the usual .05 threshold does not prove that wearables have no effect on adherence. It means this analysis did not detect a statistically reliable improvement.

That null result leaves an unresolved question. If glycemic outcomes improved without a detectable pooled adherence effect, then the education and support may have driven the measurable benefit, the adherence measure may have missed the relevant behavior, or glucose improvement may have occurred through a pathway not captured by the pooled adherence endpoint. The available trials do not establish which explanation is correct.

A 2025 systematic review by Jawad et al. reached a compatible conclusion in type 1 diabetes: digital interventions improved adherence when structured behavioral support was built into the intervention. This is not a direct type 2 diabetes result, and it should not be treated as one. It does reinforce the more general practical point that data delivery alone has a weak evidence base as a behavior-change strategy.

For someone with type 2 diabetes, the evidence-based intervention is CGM plus structured support—not a sensor alone.

Newer CGM reviews refine the question, not the verdict

CGM-specific reviews published after Kamei focus more tightly on adults with type 2 diabetes. Jancev et al.'s 2024 systematic review and meta-analysis assessed CGM outcomes including HbA1c, time in range, time below range, and time above range in adults with type 2 diabetes. Rizos et al.'s 2025 review of randomized controlled trials considered CGM across type 1 diabetes, type 2 diabetes, and diabetes during pregnancy.

These analyses are more relevant to CGM specifically than Kamei's broad wearable review, which pooled accelerometers, CGMs, and smartwatches across diabetes, COPD, and cardiac disease. That broader pooling makes it impossible to assign its diabetes effect estimate to CGM technology alone. The full pooled quantitative estimates from the newer reviews are not available here, so precision would be theater.

Lahiri et al. cite a separate systematic review by Kong et al. reporting real-time CGM HbA1c change of up to 0.5 percentage points in type 2 diabetes. That is an upper-bound figure rather than a pooled mean, and it should not be mechanically compared with Kamei's −0.69% mean difference. The reviews differ in eligibility criteria, device generations, and time periods. Still, newer literature does not establish that newer CGM hardware has increased the size of the benefit in type 2 diabetes.

Type 1 diabetes has a stronger and different evidence base

CGM has a more established role in type 1 diabetes, where continuous information can directly support insulin decisions. Dicembrini et al.'s 2021 meta-analysis of randomized trials found significant improvements in time in range and HbA1c with real-time CGM in type 1 diabetes. Those results provide useful context, but they do not automatically transfer to type 2 diabetes, where treatment regimens and the clinical role of CGM may differ.

Device category also matters. A 2024 meta-analysis by Chen et al., which included six studies and 1,516 adults with type 1 diabetes, found better glycemic control with real-time CGM than with flash glucose monitoring. Three of its six studies were randomized and three were observational. "CGM" is therefore too broad a label when comparing outcomes; real-time and flash systems do not necessarily produce equivalent results.

Metrics are useful, but they need context

CGM reports often include the glucose management indicator, or GMI, an estimate of HbA1c derived from sensor glucose data. Fang et al.'s 2023 prospective cohort study assessed GMI in 144 adults with type 2 diabetes and obstructive sleep apnea who were not using insulin. Participants wore Dexcom G4 and Abbott Libre Pro sensors for up to four weeks. The mean difference between laboratory HbA1c and GMI was 0.12 to 0.14 percentage points. That supports GMI's use as a management metric in this population, but it does not show that seeing GMI improves health behavior or clinical outcomes.

Likewise, Bai et al.'s 2025 CGMap study analyzed 528 people with type 2 diabetes from a Chinese randomized trial to characterize CGM-derived measures and their clinical correlations. It expands knowledge of how metrics such as time in range, glucose variability, and estimated HbA1c behave in a non-Western population. It is data characterization, not evidence that CGM feedback itself changes metabolism.

Consumer CGM for healthy adults remains untested

The popular wellness use case has a conspicuous evidence gap. There is no randomized controlled trial in this evidence base that tests CGM feedback as a primary metabolic-optimization intervention in adults without diabetes. Zaman et al.'s 2024 randomized trial used CGM to measure continuous glucose levels while comparing early time-restricted eating plus daily caloric restriction with caloric restriction alone in non-diabetic adults. In that study, the sensor was an outcome-measurement tool, not the intervention.

That distinction prevents a common leap: a trial that uses CGM to observe dietary effects cannot show that wearing a CGM causes people without diabetes to improve metabolic health. The absence of such trials does not show that consumer CGM is useless. It shows that claims of metabolic optimization in healthy adults currently rest on hypothesis and commercial practice, not controlled evidence.

What to do with this evidence

For pharmacologically managed type 2 diabetes, CGM paired with coaching, feedback, education, and accountability can produce a statistically significant HbA1c improvement of roughly 0.5% to 0.69% at three months. That is a reasonable basis to discuss CGM-enabled care with a clinician, especially when the program includes support for acting on the data.

Do not assume the sensor supplies that support by itself. The controlled trials do not isolate its independent effect, pooled adherence did not improve significantly, and long-term outcomes remain uncertain. For healthy people pursuing "metabolic optimization," the controlled trial evidence needed to justify the claim has not yet arrived.